Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA…
Month: June 2022
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
BridgeBio Pharma to Participate in June Investor Events
PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”…
Radius Files Definitive Proxy and Mails Letter to Stockholders
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman,…
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) — Biogen and…
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator…
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage…
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO),…
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA…
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying…
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
PRESS RELEASE Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal…
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two…
Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention
CHATHAM, N.J., June 06, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix…
XORTX Welcomes New Member to the Board of Directors and Appoints Chair
CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’
– Management to host the webinar in ASLAN’s A⁴ series on Wednesday, June 22, 2022, at…
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
Topline results to be shared during the clinical trial update platform session CHOP preclinical data…
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd (NASDAQ: TLSA) (“Tiziana”…
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in…
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
MIAMI, June 06, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused…